{
    "ticker": "UNTY",
    "name": "Unity Biotechnology, Inc.",
    "description": "Unity Biotechnology, Inc. is a pioneering biotechnology company focused on developing therapeutics to extend healthspan and combat age-related diseases. Founded in 2014 and headquartered in South San Francisco, California, Unity is at the forefront of research aimed at eradicating senescent cells, which are aging cells that contribute to various degenerative conditions. The company\u2019s innovative approach leverages its proprietary technology platform to create targeted treatments that aim to rejuvenate tissues and restore function in the aging population. Unity is committed to advancing its lead product candidate, UBX1325, which is being developed for the treatment of age-related eye diseases. The company also explores additional indications across various diseases associated with aging. With a strong commitment to scientific rigor and collaboration, Unity is actively engaging in partnerships with academic institutions and industry leaders to accelerate the development of its therapies. The mission of Unity is to transform the understanding of aging and develop effective interventions that promote healthier, longer lives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2014",
    "website": "https://www.unitybiotechnology.com",
    "ceo": "Anja K. K. Kuhl",
    "social_media": {
        "twitter": "https://twitter.com/UnityBiotech",
        "linkedin": "https://www.linkedin.com/company/unity-biotechnology/"
    },
    "investor_relations": "https://ir.unitybiotechnology.com",
    "key_executives": [
        {
            "name": "Anja K. K. Kuhl",
            "position": "CEO"
        },
        {
            "name": "Gregory L. E. C. R. M. J. H. G. Enzler",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "UBX1325"
            ]
        }
    ],
    "seo": {
        "meta_title": "Unity Biotechnology, Inc. | Extending Healthspan Through Innovative Therapeutics",
        "meta_description": "Unity Biotechnology, Inc. focuses on developing therapeutics targeting age-related diseases to enhance healthspan. Explore our innovative research and commitment to aging health.",
        "keywords": [
            "Unity Biotechnology",
            "Biotechnology",
            "Age-related Diseases",
            "Healthspan",
            "Senescence",
            "UBX1325"
        ]
    },
    "faq": [
        {
            "question": "What does Unity Biotechnology focus on?",
            "answer": "Unity Biotechnology focuses on developing therapeutics to extend healthspan and combat age-related diseases."
        },
        {
            "question": "Who is the CEO of Unity Biotechnology?",
            "answer": "Anja K. K. Kuhl is the CEO of Unity Biotechnology, Inc."
        },
        {
            "question": "Where is Unity Biotechnology headquartered?",
            "answer": "Unity Biotechnology is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What is Unity's lead product candidate?",
            "answer": "Unity's lead product candidate is UBX1325, developed for the treatment of age-related eye diseases."
        },
        {
            "question": "When was Unity Biotechnology founded?",
            "answer": "Unity Biotechnology was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NVTA",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}